Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.43
+0.10 (1.88%)
Mar 25, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Atea Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $8.00, which forecasts a 47.33% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $10.
Price Target: $8.00 (+47.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Atea Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +84.16% | Mar 9, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $6.2 → $6 | Hold | Maintains | $6.2 → $6 | +10.50% | Apr 11, 2025 |
| Morgan Stanley | Morgan Stanley | Sell → Hold Upgrades $2 → $6.88 | Sell → Hold | Upgrades | $2 → $6.88 | +26.70% | Aug 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Aug 10, 2023 |
| JP Morgan | JP Morgan | Hold Maintains $12 → $8 | Hold | Maintains | $12 → $8 | +47.33% | Mar 16, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.07M
EPS This Year
-1.94
from -1.94
EPS Next Year
-1.56
from -1.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 64.0M | |
| Avg | n/a | 31.1M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -2.00 | -1.61 |
| Avg | -1.94 | -1.56 |
| Low | -1.86 | -1.50 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.